Who are Pulmicort Respules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Durezol, Arnuity Ellipta, Omnaris, Omnaris, Mifeprex, Lotemax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/budesonide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Pulmicort Respules — Competitive Intelligence Brief

Pulmicort Respules (BUDESONIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid [EPC]. Area: Immunology.

marketed Corticosteroid [EPC] Glucocorticoid receptor Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Pulmicort Respules (BUDESONIDE) — AstraZeneca K.K..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pulmicort Respules TARGET	BUDESONIDE	AstraZeneca K.K.	marketed	Corticosteroid [EPC]	Glucocorticoid receptor	1994-01-01
Durezol	DIFLUPREDNATE	Novartis	marketed	difluprednate	Glucocorticoid receptor	2008-01-01
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	marketed	Corticosteroid	Glucocorticoid receptor	2007-01-01
Omnaris	CICLESONIDE	Covis	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	Alvesco	Takeda Gmbh	marketed	ciclesonide	Glucocorticoid receptor	2006-01-01
Mifeprex	MIFEPRISTONE	Corcept Therap	marketed	Progestin Antagonist [EPC]	Glucocorticoid receptor	2000-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	marketed	Corticosteroid	Glucocorticoid receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-09 — Pulmicort Respules · 8975243 · Method of Use · US
2026-11-09 — Pulmicort Respules · 11197822 · Formulation · US
2026-11-09 — Pulmicort Respules · 8497258 · Method of Use · US
2026-11-09 — Pulmicort Respules · 11413296 · Formulation · US
2026-11-09 — Pulmicort Respules · 9119863 · Method of Use · US
2026-11-09 — Pulmicort Respules · 8679545 · Formulation · US
2028-02-01 — Omnaris · 8371292 · US
2028-11-12 — Pulmicort Respules · 11357859 · Method of Use · US
2028-11-22 — Pulmicort Respules · 10293052 · Formulation · US
2029-05-07 — Pulmicort Respules · 8491932 · Formulation · US
2029-08-01 — Pulmicort Respules · 9050368 · Formulation · US
2029-08-03 — Pulmicort Respules · 8324192 · Method of Use · US
2031-09-07 — Pulmicort Respules · 10660858 · Formulation · US
2031-09-07 — Pulmicort Respules · 10307375 · Formulation · US
2031-09-07 — Pulmicort Respules · 9132093 · Formulation · US
2031-09-07 — Pulmicort Respules · 9192581 · Formulation · US
2031-09-07 — Pulmicort Respules · 8895064 · Formulation · US
2033-05-03 — Lotemax · 9393213 · Formulation · US
2033-05-03 — Lotemax · 10646436 · Formulation · US
2033-05-03 — Lotemax · 11872318 · Formulation · US
2033-05-03 — Lotemax · 11642317 · Formulation · US
2033-05-03 — Lotemax · 9056057 · Formulation · US
2033-05-03 — Lotemax · 9532955 · Method of Use · US
2033-05-03 — Lotemax · 10058511 · Formulation · US
2033-05-03 — Lotemax · 11219596 · Method of Use · US
2033-05-03 — Lotemax · 11219597 · Method of Use · US
2033-05-03 — Lotemax · 11596599 · Method of Use · US
2033-05-03 — Lotemax · 10857096 · Method of Use · US
2033-05-03 — Lotemax · 10864219 · Method of Use · US
2033-05-03 — Lotemax · 10945948 · Method of Use · US

Sponsor landscape (Corticosteroid [EPC] class)

Eurofarma · 2 drugs in this class
· 2 drugs in this class
Astellas Pharma · 1 drug in this class
AstraZeneca K.K. · 1 drug in this class
Generic (originally Merck) · 1 drug in this class
Generic (originally Merck/Upjohn) · 1 drug in this class
Generic (originally Schering) · 1 drug in this class
National Jewish Health · 1 drug in this class
Padagis Us · 1 drug in this class
Ptc Therap · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pulmicort Respules — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab